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Introduction. Enterococcus spp. is considered as important 
etiological agents of nosocomial infections. However, a little is 
known about the epidemiology of vancomycin resistant Entero-
coccus faecalis (VREF). The aim of this study was to investigate 
the frequency of VREF and detecting of two prevalent resistance 
genes (vanA, vanB) at Children Medical Center Hospital, an 
Iranian referral pediatric Hospital.
Materials and methods. During January 2013 to December 
2013, 180 E. faecalis  were isolated from clinical samples of 
hospitalized children. Antimicrobial testing was performed by 
Kirby-Bauer disk diffusion to gentamicin, amikacin, ceftriax-
one, cefotaxime, ceftazidim, cefixime, piperacillin/tazobactam, 
cefepime, trimethoprim/sulfamethoxazole, erythromycin, clinda-
mycin, linezolide and E-test method vancomycin and teicoplanin 
according to Clinical Laboratories Standards Institute (CLSI). 
Two prevalent resistance genes (vanA, vanB) were investigated 
in VREF isolates.
Results. Seventy-five (42%) of patients were male and 105 (58%) 
were female. Mean age of patients was 34.74 months. Cephalo-
sporin resistance was found in majority of E. faecalis isolates 
(98.7 to ceftazidim, 95% to cefixime, 93.3% to ceftriaxone, and 
89.4% to cefotaxime). Most of the isolated were susceptible to 
cefepime (91.7%). In addition, high level of erythromycin and 
clindamycin resistance was reported (93.4% and 91.2%). There 
were no linezolid-resistant E. faecalis among all isolates. Teico-
planin resistance was observed in 13.8% of E. faecalis (n = 25). 
Minimum Inhibitory concentration (MIC) ≥ 32 µg/ml for vanco-
mycin was found in 29 isolates (16%) and vanA gene was detected 
in 21 (72%) VREF strains, while vanB gene was not detected in 
any of these isolates. The mortality rate of all cases was 3.4%.
Conclusions. This study revealed high rate of vancomycin 
resistance in E. faecalis strains. Therefore, periodic surveillance 
of antibacterial susceptibilities is highly recommended to detect 
emerging resistance. 
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Summary
Introduction
Enterococci have emerged as important nosocomial 
pathogens in the last few decades. Nowadays, few 
antimicrobials are active against enterococcal spe-
cies and intrinsic resistance to several clinically used 
antimicrobials agents, making them important no-
socomial pathogens [1]. Enterococcus faecalis can 
acquire resistance via various forms of conjugation 
and spread these genes through conjugative transpo-
sons, pheromone-responsive plasmids, or broad-host-
range plasmids [1]. The increasing rate of vancomy-
cin resistance Enterococcus (VRE) has emerged as 
the global concern [2].The prevalence of VRE varies 
widely according to outbreak situations [3]. In noso-
comial settings, Enterococcus faecium accounts for 
majority of VRE infections and E. faecalis constitutes 
only 2-20% of VRE isolates, depending on geographi-
cal location and healthcare facility [4].
A little is known about the epidemiology of vanco-
mycin resistant E. faecalis (VREF) [5, 6]. PCR-based 
screening can rapidly detects the presence of VRE 
and help early prevention of VRE spread [3]. The 
screening of critically ill patients at high risk of VRE 
colonization, is recommended to prevent and control 
of VRE transmission [3]. Currently, eight phenotypic 
variants of acquired glycopeptide resistance in ente-
rococci have been reported (VanA, VanB, VanD, VanE, 
VanG, VanL, VanM, and VanN), with one type of in-
trinsic resistance (VanC) which belongs to Enterococ-
cus gallinarum and Enterococcus casseliflavus [7]. 
The vanA and vanB phenotypes confer high-level 
vancomycin resistance (MIC > 64 μg/mL and is more 
prevalent among other phenotypes [8].
Data on the prevalence of VREF are scarce in Iran [5]. 
The aim of this study was to investigate the frequency 
of VREF and detection of two prevalent resistance 
genes (vanA, vanB) in pediatric population in an Ira-
nian referral pediatric Hospital.




We performed a study of patients in whom E. faeca-
lis were detected in clinical samples between January 
2013, and December 2013, at Children Medical Center 
Hospital, tertiary care and teaching hospital in Tehran, 
Iran. A total of 180 E. faecalis isolates were analyzed. 
All isolates were identified using standard microbiology 
methods [9].
Microbiological methods
Antimicrobial testing was performed by Kirby-Bauer 
disk diffusion method to detect resistance to gentamicin, 
amikacin, ceftriaxone, cefotaxime, ceftazidim, cefixime, 
piperacillin/tazobactam, cefepime, trimethoprim/sul-
famethoxazole, erythromycin, clindamycin, linezolide 
according to Clinical Laboratories Standards Institute 
(CLSI) [10].
Antimicrobial resistance to vancomycin and teicoplanin 
was detected by measuring minimum inhibitory concen-
trations using E-test.
Vancomycin and teicoplanin sensitivity were evaluated 
by the E-test (AB BIODISK, Solna, Sweden) method. 
The results were read after 24h incubation at 37°C. MIC 
of ≤ 4 (μg/mL) was considered as susceptibility, MIC 
8 to16 and  ≥ 32 were considered as intermediate and 
resistant, respectively [10].
DNA Extraction
DNA was extracted from VREF isolates using QIAamp 
DNA Mini Kit (QIAGEN) according to the manufac-
turer’s instruction
Polymerase chain reaction (PCR) amplification of vanA 
and vanB genes
The PCR assay was performed in a total volume of 
25 μl containing 10 mM Tris-HCl (pH 8.3), 50 mM 
KCl, 1.5 mM MgCl2, 0.2 mM each deoxynucleotide 
triphosphate (dATP, dCTP, dGTP, and dTTP), and 0.5 U 
of Taq DNA polymerase with the following primer 
F:5′-CATGAATAGAATAAAAGTTGCAATA-3′ and 
5′-CCCCTTTAACGCTAATACGATCAA-3′ for am-
plification of vanA and F: 5′-GTGACAAACCGGAG-
GCGAGGA-3′ and R: 5′-CCGCCATCCTCCTG-
CAAAAAA-3′ for amplification vanB gene [11]. DNA 
amplification was carried out with the following thermal 
cycling profile: initial denaturation at 94°C for 5 min, 30 
cycles of amplification (denaturation at 94°C for 1 min, 
annealing at 54°C for 1 min, and extension at 72°C for 
1 min), and a final extension at 72°C for 10 min. E. fae-
cium BM4147 (vanA-positive) and E. faecalis V583 
(vanB-positive) were used as positive controls. PCR 
products were analyzed on a 1% agarose gel with 0.5 × 
Tris-borate-EDTA buffer. A 100-bp DNA ladder (New 
England Biolabs, Beverly, Mass.) was used as the mo-
lecular size marker. The gels were stained with gel red 
and photographed under UV light. 
Results
In this study 180 samples of E. faecalis were obtained 
from children aged 1month to 12 years old. Seventy-five 
(42%) of patients were male and 105 (58%) were fe-
male. Mean age of patients was 34.74  months. Thirty 
eight of the patients were hospitalized in urology ward, 
whereas the others were distributed in gastroenterol-
ogy ward (n = 19), nephrology ward (n = 20), infectious 
ward (n  =  18), emergency ward (n  =  40), hematology 
ward (n = 4), NICU (n = 17), PICU (n = 8), surgery ward 
(n = 7), cardiology ward (n = 6) and rheumatology ward 
(n  =  3). The mortality rate of all cases was 3.4% and 
10% of patients with VREF infection died.
Antimicrobial susceptibility was determined for a vari-
ety of antibiotics (Tab. I). Cephalosporin resistance was 
found in majority of E. faecalis isolates (98.7 to ceftazi-
dim, 95% to cefixime, 93.3% to ceftriaxone, and 89.4% 
to cefotaxime). Most of the isolated were susceptible 
to cefepime (91.7%). In addition, high level of erythro-
mycin and clindamycin resistance was reported (93.4% 
and 91.2%). More than 90% of isolated were resistant to 
ceftriaxone, cefotaxime, cefixime, ceftazidim and clin-
damycin. There was no linezolid-resistant E. faecalis 
among all isolates. Teicoplanin resistance was observed 
in 13.8% of E. faecalis (n = 25). MIC ≥ 32 µg/ml for van-
comycin was found in 29 isolates (16%). Among resist-
ant group, 12(41.4%) were male and 17(58.6%) cases 
were female with a mean age of 27.9 months. Ten pa-
tients with VREF were hospitalized in urology ward, the 
others were distributed in infectious ward (n = 3), CICU 
(n = 8), gastroenterology ward (n = 6) and emergency 
(n = 2). There were no significant differences between 
the age, sex and wards of the patients with VREF or van-
comycin susceptible isolates (P value ≥ 0.05). 
Antimicrobial susceptibility of VREF isolates was 
shown in Table 2.Among all patients with VREF iso-
lates, 117 (65%) and 20 (69%) cases had underlining 
disease, respectively.







Gentamycin 134 (74.4) 46 (25.6)
Amikacin 110 (61.1) 70 (38.9)
Ceftrixone 168 (93.3) 12 (6.7)
Cefotaxime 161 (89.4) 19 (10.6)
Cefixime 171 (95) 9 (5)
Ceftazidim 177 (98.7) 13 (1.3)
Piperacillin/ tazobactam 100 (56) 80 (44)
Cefepime 15 (8.2) 165 (91.7)
Trimethoprim- sulphametoxazole 139 (77.5) 41 (22.5)
Erythromycin 168 (93.4) 12 (6.6)
Clindamycin 164 (91.2) 16 (8.8)
Linezolide 0 (0) 180 (100)
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Amplification of  vanA,  vanB  targets produced distinct 
bands corresponding to their respective molecular sizes 
(1,030 bp for vanA and 433 bp for vanB). Among VREF, 
vanA gene was detected in 21 (72%) isolates, while vanB 
gene was not detected in any of these isolates. vanA gene 
was found in 13 girls (62%) and 8 boys (38%) (p val-
ue ≥  0.05).
Discussion
The emergence of VRE as an important nosocomial 
pathogen is due to its propensity for colonization of the 
gastrointestinal (GI) tract, persistence in hospital envi-
ronments, genome plasticity, mobile genetic elements, 
and increased mortality [12]. The epidemiology of VRE 
varies from one hospital to another, which depends on 
several factors including the hospital size, patient popu-
lation, antibiotic usage patterns and geographic location. 
According to earlier reports, risk factors that increase the 
likelihood of VRE infection or colonization can be due 
to host factors, hospital-specific factors and antibiotic 
usage [4]. 
The antimicrobial susceptibility of Enterococcus  spp. 
showed higher resistant pattern to a majority of antibi-
otics compare to our previous hospital report in 1996-
2000 [13].
Analysis of our results similar to other studies indicate 
vanA gene as common determinant for glycopeptide re-
sistance in Enterococcus spp.  [14-17]. VanA is respon-
sible for most of the human cases of VRE around the 
world  [7]. In addition, the  vanA operon can easily be 
transferred through acquired resistance [18]. Our previ-
ous study demonstrated that clonal dissemination was a 
major mechanism of the spread of these isolates [5]. The 
majority of E. faecalis colonization occurs in the gastro-
intestinal tract infection (GI) and to a lesser extent on the 
skin, in the genitourinary tract, and in the oral cavity [7, 
8, 19]. When GI colonization with VRE occurs, it can 
persist for months to years. In addition, and efforts for 
decolonization are typically transitory and recurrence of 
VRE may occur days or weeks later [7, 19]. The com-
mon pathway of nosocomial VRE acquisition might be 
via person-to-person contact or exposure to contami-
nated objects. Health care workers’ hands are the most 
consistent source of transmission and it has been report-
ed that VRE can persist for up to 60 minutes on hands 
and as long as 4 months on surfaces [7, 20]. Therefore, 
healthcare facilities need a comprehensive infection 
control program in order to decrease the transmission of 
VRE among patients. 
The emergence of VRE is also due to the inappropriate 
use of cephalosporin as well as poor hospital infection 
control measures  [21]. Long duration of hospital stay 
and high rate of antibiotics treatment are the most fre-
quently reported risk factor for multi-resistance Entero-
cocci colonization and infection.
Another concern about VREF is the possible transfer of 
vanA from E. faecalis to S. aureus [22]. E. faecalis vanA-
carrying plasmid was found to encode a response to sex 
pheromone and it raises concern about the potential up-
take of vanA from Enterococci by a pheromone-related 
process in S. aureus [23].
Our study highlights further intervention for controlling 
the spread of VRE. Active periodic surveillance cultures 
(or molecular testing) of patients at highest risk for car-
riage, decontaminating the hands of healthcare workers 
using an antiseptic-containing preparation before and 
after all patient contact, adherence to barrier precautions 
(i.e., gloves and gowns) and cohorting colonized and/
or infected patients; and cleaning of occupied rooms by 
patient with VRE are highly recommended [24, 25].
In conclusion, in this study high frequency of vancomy-
cin resistance in E. faecalis strains was fournd. There-
fore, periodic surveillance of antibacterial susceptibili-
ties is highly recommended to detect emerging resist-
ance.
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